SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
Drug Development
Daiichi Sankyo’s Mirogabalin Displays Significant Reduction in Post-SCI Neuropathic Pain
A phase 3 study from Daiichi Sankyo Company conducted in Japan, South Korea and Taiwan found that mirogabalin, an orally administered gabapentinoid, was associated with a significantly greater improvement in pain among patients with central neuropathic pain after spinal cord injury compared with placebo.
December 18, 2020
 · 
3 min read
 · 
Brandon May
Antoine Yver, Executive Vice President and Global
Business
Enhertu Moves One Step Closer to Giving Gastric Cancer a Gut Punch
AstraZeneca and Daiichi Sankyo’s Enhertu received supplemental Biologics License Application acceptance and U.S. priority review for the treatment of HER2-positive metastatic gastric – or gastroesophageal junction cancer.
October 29, 2020
 · 
2 min read
 · 
Heather McKenzie
Business
Daiichi Sankyo Supports Patients and Advocacy Groups for Breast Cancer Awareness Month
October is Breast Cancer Awareness month, and Daiichi Sankyo is aiming to raise awareness about one of the most common forms of cancer across the globe.
October 21, 2020
 · 
3 min read
 · 
Alex Keown
Business
Busy Rain Therapeutics Licenses 2 Oncology Assets, Closes $63 Million Series B
Privately-held Rain Therapeutics closed a $63 million Series B financing round that will be used to advance the company’s pipeline of targeted cancer therapies, including RAIN-32, its recently acquired asset from Daiichi Sankyo.
September 3, 2020
 · 
2 min read
 · 
Alex Keown
Business
AstraZeneca and Daiichi Sankyo Ink $6 Billion Cancer Pact
AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo Company for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) for multiple cancer types.
July 27, 2020
 · 
3 min read
 · 
Mark Terry
Business
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
The diagnostic tool will use Thermo Fisher’s next-generation sequencing (NGS)-based Oncomine Dx Target Test to identify HER2 (human epidermal growth factor receptor 2) gene mutations.
June 23, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: June 12
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
June 11, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Business
Daiichi Sankyo, Syneos Health Eye New Cancer Therapies with Collaboration Agreement
Daiichi Sankyo announced on May 28 that it had entered an agreement with Syneos Health to form a coalition dedicated to bringing new cancer therapies to patients in a safe and effective manner.
June 5, 2020
 · 
3 min read
 · 
Krystle Vermes
Policy
Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute
In a filing with the court, Seattle Genetics claimed the right to arbitration to resolve the dispute with Daiichi Sankyo, as is required by the 2008 collaboration agreement.
December 3, 2019
 · 
2 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
Pharm Country
Data Across Daiichi Sankyo DXd ADC Portfolio at 2022 SABCS Demonstrates Bold Progress in Advancing Treatment for Patients with Breast Cancer
November 21, 2022
 · 
26 min read
Business
Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML
October 24, 2022
 · 
3 min read
Pharm Country
Quizartinib Granted Priority Review in the U.S. for Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
October 24, 2022
 · 
7 min read
BioCapital
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
September 11, 2022
 · 
34 min read
Pharm Country
ENHERTU® Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2 Mutant Metastatic Non-Small Cell Lung Cancer
September 11, 2022
 · 
33 min read
BioMidwest
DS-7300 Continues to Show Promising Durable Response in Patients with Several Types of Advanced Cancer
September 10, 2022
 · 
11 min read
Pharm Country
Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO
September 6, 2022
 · 
25 min read
Drug Development
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
August 15, 2022
 · 
24 min read
Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
August 12, 2022
 · 
30 min read
Policy
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
August 11, 2022
 · 
30 min read
Load More